Literature DB >> 30144981

Impact of rotor ablation in non-paroxysmal AF patients: Findings from the per-protocol population of the OASIS trial at long-term follow-up.

Sanghamitra Mohanty1, Carola Gianni1, Chintan Trivedi1, Tamara Metz1, Rong Bai2, Amin Al-Ahmad1, Shane Bailey1, John David Burkhardt1, G Joseph Gallinghouse1, Rodney Horton1, Patrick M Hranitzky1, Javier E Sanchez1, Luigi Di Biase1, Andrea Natale3.   

Abstract

The objective of this study was to evaluate the long-term efficacy of FIRM ablation with PVAI vs PVAI plus posterior wall isolation (PWI) and non-PV trigger ablation in persistent (PeAF) and long-standing persistent AF (LSPAF) patients. The procedure time was recorded to be 180.6 ± 35.9 and 124.03 ± 45.4 minutes in the FIRM+PVI and PVI + PWI + non-PV trigger ablation group respectively. At 24-month follow-up, 24% (95% CI 8.7%-37.8%) in the FIRM-ablation group and 48% (95% CI 27.6-63.3%) in the non-PV trigger ablation group remained arrhythmia-free off-antiarrhythmic drugs after a single procedure. Clinical Trial Registration:ClinicalTrials.gov (Identifier: NCT02533843).
Copyright © 2018 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2018        PMID: 30144981     DOI: 10.1016/j.ahj.2018.05.021

Source DB:  PubMed          Journal:  Am Heart J        ISSN: 0002-8703            Impact factor:   4.749


  7 in total

Review 1.  Comparing the efficacy of catheter ablation strategies for persistent atrial fibrillation: a Bayesian analysis of randomized controlled trials.

Authors:  Sijia Wu; Hongkai Li; Shaolei Yi; Jianming Yao; Xueming Chen
Journal:  J Interv Card Electrophysiol       Date:  2022-07-04       Impact factor: 1.900

Review 2.  Future Directions for Mapping Atrial Fibrillation.

Authors:  Junaid Ab Zaman; Andrew A Grace; Sanjiv M Narayan
Journal:  Arrhythm Electrophysiol Rev       Date:  2022-04

Review 3.  Novel approaches to mechanism-based atrial fibrillation ablation.

Authors:  Jorge G Quintanilla; Shlomo Shpun; José Jalife; David Filgueiras-Rama
Journal:  Cardiovasc Res       Date:  2021-06-16       Impact factor: 10.787

4.  Ablation Therapy for Persistent Atrial Fibrillation.

Authors:  Ikechukwu Ifedili; Kristina Mouksian; David Jones; Ibrahim El Masri; Mark Heckle; John Jefferies; Yehoshua C Levine
Journal:  Curr Cardiol Rev       Date:  2022

Review 5.  Catheter Ablation of Atrial Fibrillation: State of the Art and Future Perspectives.

Authors:  Laura Rottner; Barbara Bellmann; Tina Lin; Bruno Reissmann; Tobias Tönnis; Ruben Schleberger; Moritz Nies; Christiane Jungen; Leon Dinshaw; Niklas Klatt; Jannis Dickow; Paula Münkler; Christian Meyer; Andreas Metzner; Andreas Rillig
Journal:  Cardiol Ther       Date:  2020-01-02

6.  RADAR: A Multicenter Food and Drug Administration Investigational Device Exemption Clinical Trial of Persistent Atrial Fibrillation.

Authors:  Subbarao Choudry; Moussa Mansour; Sri Sundaram; Duy T Nguyen; Srinivas R Dukkipati; William Whang; Paul Kessman; Vivek Y Reddy
Journal:  Circ Arrhythm Electrophysiol       Date:  2020-01-16

Review 7.  Mapping Technologies for Catheter Ablation of Atrial Fibrillation Beyond Pulmonary Vein Isolation.

Authors:  Giulio La Rosa; Jorge G Quintanilla; Ricardo Salgado; Juan José González-Ferrer; Victoria Cañadas-Godoy; Julián Pérez-Villacastín; Nicasio Pérez-Castellano; José Jalife; David Filgueiras-Rama
Journal:  Eur Cardiol       Date:  2021-05-17
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.